-
www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/hiv-prep-guide-2020_0.pdf
January 01, 2020 - Regardless of your sex, sexual orientation,
or gender identity, PrEP might be right for
you if ANY
-
www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-230-section-5-table-5.pdf
January 01, 2010 - committee recommends that individuals 2 to
18 years of age with BMI of ≥95th percentile
for age and gender … be considered obese and
individuals with BMI of ≥85th percentile but
<95th percentile for age and gender … The definition of overweight is age-
and gender-specific BMI at the ≥85th to 94
th
percentile; obesity … is age- and gender-specific
BMI at the ≥95th percentile. … BMI percentile for
age and gender is the preferred measure for
detecting overweight in children and
-
www.uspreventiveservicestaskforce.org/uspstf/document/draft-research-plan/sexually-transmitted-infections
January 16, 2025 - modalities that have been developed to address the needs and concerns of specific populations with regard to gender … studies, descriptions of study populations vary in their recognition of the presence of transgender, gender … nonbinary, and gender expansive individuals. … We will generally use the gender terminology used to describe included study populations; however, since … anatomic, social, and behavioral factors contribute to STI risk, we will aim to characterize gender
-
psnet.ahrq.gov/node/866934/psn-pdf
October 09, 2024 - how-americas-health-care-system-fails-women-pain
Appropriate treatment of pain is a complicated process vulnerable to racial, ethnic, and gender … racial-bias-pain-assessment-and-treatment-recommendations-and-false-beliefs-about-biological
https://psnet.ahrq.gov/issue/gender-biases-estimation-others-pain
-
psnet.ahrq.gov/node/50727/psn-pdf
December 11, 2019 - This news story
discusses racial and gender bias as common factors that reduce the accuracy and effectiveness … your-diagnosis-was-wrong-could-doctor-bias-have-been-factor
https://psnet.ahrq.gov/issue/prejudice-perceptions-physicians-influence-race-and-gender-evaluations-medical-errors
-
www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/0085textdescription.pdf
January 01, 2012 - Individual Characteristic Patient Characteristic Gender HL7 (2.16.840.1.113883.5.1) 2.16.840.1.113883.1.11.1 … Individual Characteristic Patient Characteristic Gender of Newborn HL7 (2.16.840.1.113883.5.1) 2.16.840.1.113883.1.11.1 … Attribute Attribute: Result Present "X" n/a n/a n/a This attribute is applied to the value set 'Gender … 2.16.840.1.114222.4.11.831
PATIENT CHARACTERISTIC
Payer
2.16.840.1.113883.221.5
PATIENT CHARACTERISTIC
Gender … 2.16.840.1.113883.1.11.1
PATIENT CHARACTERISTIC
Age at Delivery
2.16.840.1.113883.3.526.2.1434
PHYSICAL EXAM
Finding
Gender
-
psnet.ahrq.gov/node/843431/psn-pdf
January 02, 2001 - https://psnet.ahrq.gov/issue/girl-who-cried-pain-bias-against-women-treatment-pain
Gender inequities … This review summarizes
studies on gender differences in experiences and treatment of pain, and assessment … psnet.ahrq.gov/issue/unwell-women-misdiagnosis-and-myth-man-made-world
https://psnet.ahrq.gov/issue/gender-biases-estimation-others-pain
-
psnet.ahrq.gov/node/841788/psn-pdf
December 21, 2022 - https://psnet.ahrq.gov/issue/heart-disease-iuds-how-doctors-dismiss-womens-pain
Gender and racial bias … breast-cancer-treatment-delays-socioeconomic-and-health-care-access-latent-classes-black-and
https://psnet.ahrq.gov/issue/gender-biases-estimation-others-pain
-
effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables1.xls
May 29, 2025 - ASPARAGINASE 95 and over - - - - - - - - -
Miscellaneous Biologic Nonblood Products ASPARAGINASE Gender … - 1.0% -
Kinase Inhibitors DASATINIB 95 and over - - - - - - - - -
Kinase Inhibitors DASATINIB Gender … Modifiers DENILEUKIN 95 and over 0.3% - - 0.2% - - - - -
Biologic Response Modifiers DENILEUKIN Gender … - - -
Kinase Inhibitors EVEROLIMUS 95 and over - - - - - - - - -
Kinase Inhibitors EVEROLIMUS Gender … - - - -
Kinase Inhibitors GEFITINIB 95 and over - - - - - - - - -
Kinase Inhibitors GEFITINIB Gender
-
effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables.xls
May 29, 2025 - ASPARAGINASE 95 and over - - - - - - - - -
Miscellaneous Biologic Nonblood Products ASPARAGINASE Gender … - 1.0% -
Kinase Inhibitors DASATINIB 95 and over - - - - - - - - -
Kinase Inhibitors DASATINIB Gender … Modifiers DENILEUKIN 95 and over 0.3% - - 0.2% - - - - -
Biologic Response Modifiers DENILEUKIN Gender … - - -
Kinase Inhibitors EVEROLIMUS 95 and over - - - - - - - - -
Kinase Inhibitors EVEROLIMUS Gender … - - - -
Kinase Inhibitors GEFITINIB 95 and over - - - - - - - - -
Kinase Inhibitors GEFITINIB Gender
-
www.ahrq.gov/hai/tools/mvp/modules/technical/ltvv-slides.html
October 01, 2020 - Height/gender.
Tidal volume (target and actual).
Plateau pressure.
PEEP.
ARDS status. … vent status (Y/N/E), place to circle if Vent Mode category (1,2, or 3), and place to record height and gender … Circle patient’s gender.
-
www.ahrq.gov/sites/default/files/2025-03/tanner-report.pdf
January 01, 2025 - The distribution and onset
age of the focal dystonias may vary by race, gender, or age, but this may … A control group was assembled in a 10:1 ratio, matching by age, gender and duration of membership in … Gender. … (e) Do the answers to (a)-(d)
vary by gender, race/ethnicity, or socioeconomic status? … (e) Variation by gender, race/ethnicity, or socioeconomic status.
Gender.
-
www.ahrq.gov/practiceimprovement/delivery-initiative/rodriguez/index.html
December 01, 2020 - Note: Adjusted analyses control for patient age, gender, race/ethnicity, and insurance status. … Note: Adjusted analyses control for patient age, gender, race/ethnicity, and insurance status. … Note: Adjusted analyses control for patient age, gender, race/ethnicity, and insurance status. … Note: Adjusted analyses control for patient age, gender, race/ethnicity, and insurance status. … Gender seemed to play a role in the implementation of CHW home visits.
-
psnet.ahrq.gov/node/860389/psn-pdf
January 10, 2024 - In this study, 852 autopsies containing
one or more DE were investigated for potential gender and/or … From 2015-2019,
however, there were no significant differences by gender, but patients identified as
-
psnet.ahrq.gov/node/859341/psn-pdf
January 01, 2024 - This review
highlights how the types and frequency of error reporting vary by race, gender, language … https://psnet.ahrq.gov/issue/assessment-bias-patient-safety-reporting-systems-categorized-physician-gender-race-and
-
psnet.ahrq.gov/web-mm/paroxysmal-supraventricular-tachycardia-masquerading-panic-attacks
September 01, 2017 - Third, while it is important for clinicians to take steps to root out personal gender bias, they should … also recognize that gender bias is also present in diagnostic standards and norms. … In cases like this one, avoiding gender-based error depends on clinicians’ individual efforts to factor … states (such as paroxysmal tachycardia) can go in both directions and do a better job of promoting gender … should recognize that the higher reported prevalence of panic disorder among women may contribute to gender
-
psnet.ahrq.gov/node/844770/psn-pdf
September 11, 2019 - utilization-role-based-head-covering-system-decrease-misidentification-operating-room
https://psnet.ahrq.gov/issue/gender-based-differences-surgical-residents-perceptions-patient-safety-continuity-care-and … https://psnet.ahrq.gov/issue/gender-based-differences-surgical-residents-perceptions-patient-safety-continuity-care-and
-
effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables1.pdf
May 29, 2025 - Continuous AB FFS Enrollment Prior to First Relevant Claim by Class of Drug, Active Ingredient, Age, Gender … antibodies Alemtuzumab 85 to 94 * 1.4 0.7 5.2 1.1 * * 1.5 1.2
Monoclonal antibodies Alemtuzumab Gender … antibodies Cetuximab 95 and over * 0.1 * 0.2 0.2 * 0.1 0.1 0.0
Monoclonal antibodies Cetuximab Gender … Kinase inhibitors Dasatinib 85 to 94 * 1.4 5.5 3.2 1.0 * * 1.0 *
Kinase inhibitors Dasatinib Gender … 0.9
Kinase inhibitors Imatinib 95 and over * * 0.4 0.2 0.2 * * * *
Kinase inhibitors Imatinib Gender
-
effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables.pdf
May 29, 2025 - Continuous AB FFS Enrollment Prior to First Relevant Claim by Class of Drug, Active Ingredient, Age, Gender … antibodies Alemtuzumab 85 to 94 * 1.4 0.7 5.2 1.1 * * 1.5 1.2
Monoclonal antibodies Alemtuzumab Gender … antibodies Cetuximab 95 and over * 0.1 * 0.2 0.2 * 0.1 0.1 0.0
Monoclonal antibodies Cetuximab Gender … Kinase inhibitors Dasatinib 85 to 94 * 1.4 5.5 3.2 1.0 * * 1.0 *
Kinase inhibitors Dasatinib Gender … 0.9
Kinase inhibitors Imatinib 95 and over * * 0.4 0.2 0.2 * * * *
Kinase inhibitors Imatinib Gender
-
psnet.ahrq.gov/node/839325/psn-pdf
November 02, 2022 - human-centered-design-workshops-meta-solution-diagnostic-disparities
Previous research has identified gender … human-centered-design-workshops-meta-solution-diagnostic-disparities
https://psnet.ahrq.gov/issue/flaw-medicine-addressing-racial-and-gender-disparities-critical-care